Goodwin advised AMAG Pharmaceuticals, Inc. (Nasdaq: AMAG) in the completion of its $300 million aggregate principal amount of 3.25% convertible senior notes due 2022 in an…
Standard 1 Year Membership Required
You must be a Standard 1 Year member to access this content.
Already a member? Log in here
